Biogen Idec to acquire developer of fibrosis treatment
Biogen Idec Inc has announced plans to acquire privately-owned Stromedix Inc of Cambridge, Massachusetts for $75 million upfront, plus milestones, in order to gain access to an investigational antibody for fibrotic disease.